<bill session="114" type="h" number="2069" updated="2015-06-20T06:35:49-04:00">
  <state datetime="2015-04-28">REFERRED</state>
  <status>
    <introduced datetime="2015-04-28"/>
  </status>
  <introduced datetime="2015-04-28"/>
  <titles>
    <title type="short" as="introduced">Neuromyelitis Optica Consortium Act</title>
    <title type="official" as="introduced">To amend the Public Health Service Act to create a National Neuromyelitis Optica Consortium to provide grants and coordinate research with respect to the causes of, and risk factors associated with, neuromyelitis optica, and for other purposes.</title>
  </titles>
  <sponsor id="400237"/>
  <cosponsors/>
  <actions>
    <action datetime="2015-04-28" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2015-05-01">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Department of Health and Human Services"/>
    <term name="Executive agency funding and structure"/>
    <term name="Health programs administration and funding"/>
    <term name="Hearing, speech, and vision care"/>
    <term name="Medical research"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Neurological disorders"/>
    <term name="Research administration and funding"/>
  </subjects>
  <amendments/>
  <summary>4/28/2015--Introduced.
Neuromyelitis Optica Consortium Act

This bill amends the Public Health Service Act to require the National Institutes of Health to establish, administer, and coordinate a National Neuromyelitis Optica (NMO) Consortium to:

 award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO (a neurological disease leading to blindness and paralysis); assemble a panel of experts to provide ongoing guidance and recommendations on research design and protocols; and designate a central laboratory to collect, analyze, and aggregate data from this research and to make the data and analysis available to researchers.</summary>
</bill>
